Scinai Immunotherapeutics Profit Margin

Scinai Immunotherapeutics (SCNI) currently reports a profit margin of -211.65% as of June 2026. That compares with 343.07% in the prior-year period — down 161.7% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Scinai Immunotherapeutics's profit margin history and peer comparisons.

Scinai Immunotherapeutics's profit margin decreased from 343.07% to -211.65% — a 161.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Scinai Immunotherapeutics's profit margin of -211.65% is lower than the Healthcare sector average of 13.89%. That is roughly 1624.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Scinai Immunotherapeutics's current -211.65% should be judged against Healthcare norms (sector average: 13.89%) and against SCNI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -211.65%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Scinai Immunotherapeutics, and consider following SCNI for alerts when major investors trade the stock.